• Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • FinTech
    • Gadgets & Electronics
    • Health & Bio
    • IoT
    • Marketplaces & E-commerce
    • Robotics
    • Transportation & Logistics
    • Investments
    • Ecosystem & Lists
  • Interviews
  • Events
    • ComeUp
    • NextRise
  • Governments
    • KISA
    • KISED
    • KOCCA
    • KOTRA
    • MSS
    • NIPA
    • SBA
  • Programs
    • LAUNCHPAD
    • COMEUP STARS 120
    • K-Startup Grand Challenge
    • TIPS X beSUCCESS Global Project
  • Investment Opportunities
    • Launchpad France Demoday
    • TIPS Global Demoday
    • Launchpad USA Demoday
    • Launchpad Indonesia Demoday
  • Submit an Article
  • Forums
  • register
  • login
Friday, January 15, 2021
KoreaTechDesk
No Result
View All Result
Koreatechdesk
No Result
View All Result
Home Health & Bio

Korean American VC Asia Alpha invests in Life Sciences: German cancer immunotherapies and Israeli RNA

 1,067 total views,  1 today views

Be one of the first to comment
jimbopkim by jimbopkim (KoreaTechDesk Contributor)
PUBLISHED: August 4, 2020 UPDATED: August 5, 2020
in Health & Bio
0
Bookmark(0)

Please login to bookmark

No account yet? Register

Submit post

Immatics at Nasdaq.

0
SHARES
330
VIEWS
Share on FacebookShare on Twitter

READ ALSO

Korean startups making healthcare rehabilitation better with technology 

Korean startup Neofect: Helping millions avail easy rehabilitation with smart therapeutic wearable devices

Korean-American Venture Capitalist Asia Alpha invests in life sciences companies with funding to German cancer immunotherapies and Israeli orphan diseases. Asia Alpha invested in German company Immactics N.V. and Israeli firm Eloxx Pharmaceuticals.

German company Immatics N.V. (NASDAQ: IMTX; “Immatics”), is a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies. Immatics recently announced the completion of its business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA), a special purpose acquisition company (SPAC). Immatics N.V. will commence trading its shares under the symbol “IMTX” and its warrants under the symbol “IMTXW” on the NASDAQ. Proceeds from this transaction were approximately $253 million.

About Immatics

Immatics combines the discovery of true targets for cancer immunotherapies with the right T cell receptors’ development to enable a robust and specific T cell response against these targets. This in-depth know-how is the foundation for the Adoptive Cell Therapies and TCR Bispecifics and the partnerships with global leaders in the pharmaceutical industry. Immactics is committed to delivering T cells’ power and unlocking new avenues for patients in their fight against cancer.

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting the production of functional proteins. The company recently announced that a scientific manuscript titled: “ELX-02 Generates Protein via Premature Stop Codon Read-through Without Inducing Native Stop Codon Read-through Protein”, has been published in the Journal of Pharmacology and Experimental Therapeutics.

“We are very pleased that our scientific manuscript on ELX-02 which demonstrates that ELX-02 mediates read-through of premature stop codons while maintaining the fidelity of stop codons found at the end of healthy transcripts has been published in the Journal of Pharmacology and Experimental Therapeutics” said Dr. Matthew Goddeeris, Ph.D., Vice President of Research, Eloxx Pharmaceuticals.

“This is an important finding indicating that translation integrity is preserved with target-therapeutic exposure of ELX-02, consistent with the favorable tolerability profile demonstrated across our preclinical and clinical datasets. ELX-02 is currently in Phase 2 clinical trials in cystic fibrosis patients with nonsense mutations, for whom there are few if any, treatment options available.”

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases.

These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore the production of full-length functional proteins.

ELX-02 is in the early stages of clinical development, focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx also has preclinical programs focused on rare ocular genetic disorders and polycystic kidney disease Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel, and Morristown, NJ.

About Asia Alpha

Asia Alpha is a New York-based Korean American family office investor in venture capital growth companies in Silicon Valley and Israel. Asia Alpha backs founders from seed through growth. Asia Alpha seeks to add value to each portfolio company and serves on the Board of NYU University Langone Perlmutter Cancer Hospital and has a research fund at Dana Farber Cancer Institute.   Asia Alpha is supporting diabetes management and post-operative cancer as an investor in Noom, the nutrition and chronic condition management-focused digital healthcare unicorn founded by Korean Saeju Jeong.

What’s your thoughts?
+1
1
Upvote
+1
0
Clap
+1
0
Clap
+1
2
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: arqulebreast cancerCANCERclinical trialscystic fibrosisdana farberdiabeteseloxeloxxEntrepreneursFDAfoundersgermanyhospitalimmaticsimtxInvestorisraeljournal of pharmacologykorean americanLangonelife sciencesmercknasdaqNoomNYU Perlmutterorphan diseasephase 2RNASPACVenture Capitalweight management
jimbopkim

jimbopkim

Related Posts

Korean startups making healthcare rehabilitation better with technology #Ecosystem & Lists
Ecosystem & Lists

Korean startups making healthcare rehabilitation better with technology 

January 11, 2021
Korean startup Neofect: Helping millions avail easy rehabilitation with smart therapeutic wearable devices#Health & Bio
Health & Bio

Korean startup Neofect: Helping millions avail easy rehabilitation with smart therapeutic wearable devices

January 3, 2021
Korean Startup J&T Biotech develops self-use auto-injector for allergy medication#COMEUP STARS 120
COMEUP STARS 120

Korean Startup J&T Biotech develops self-use auto-injector for allergy medication

January 4, 2021
Korean startup Exosystems makes smart knee care solution Exo-Rehab for elderly#COMEUP STARS 120
COMEUP STARS 120

Korean startup Exosystems makes smart knee care solution Exo-Rehab for elderly

December 10, 2020
Korean startup Looxid Labs to unveil cognitive care solution ‘LUCY’ for seniors at Facebook Accelerator Seoul Demo Day #AR & VR
AR & VR

Korean startup Looxid Labs to unveil cognitive care solution ‘LUCY’ for seniors at Facebook Accelerator Seoul Demo Day 

December 1, 2020
Korean startup AITRICS improving the patient-care system with its AI-driven risk prediction system #AI & Big Data
AI & Big Data

Korean startup AITRICS improving the patient-care system with its AI-driven risk prediction system 

November 26, 2020
0 0 vote
Article Rating
Subscribe
Sign up Login
Notify of
Please login to comment
0 Comments
Inline Feedbacks
View all comments

FREE NEWSLETTER

No Result
View All Result

TRENDING POSTS

  • Vietnamese startup Loship upgrades the customer experience game by combining food delivery and podcasts

     810 total views,  3 today views

  • Korean startup Letsee to launch a global version of Web-AR solution

     812 total views,  5 today views

  • Korean startup Twinny Robotics’ autonomous navigation robots help logistics companies reduce cost and save time 

     1,312 total views,  9 today views

  • Korean startup IMEMINE CEO Iksoo Park about how the SizeMine app will help fashion e-commerce reduce returns cost

     760 total views,  4 today views

  • Korean startup Riiid’s AI Education Challenge attracts over 2,700 teams around the world

     868 total views,  3 today views

  • Korean Startup Seoul Robotics’ 3D engine for Lidar sensors to make autonomous driving smarter 

     637 total views,  2 today views

  • 16th Invest Korea Week 2020 held virtually with in-depth discussions about how to thrive Post-Covid 

     750 total views,  7 today views

  • Korean startup Vogo safeguarding environment with its eco-friendly vessels for the marine industry

     742 total views,  1 today views

  • COMEUP 2020 DAY 1: COMEUP STARS pitches & K-Startup Grand Challenge Awards, Special sessions & side events

     863 total views,  3 today views

  • Korean Startup J&T Biotech develops self-use auto-injector for allergy medication

     816 total views,  2 today views

More from our network


  • ktd

  • atd

  • itd

  • ktt

  • kgd

  • kpp

  • ktp

  • kpoppost

  • ustechtimes
  • About Us
  • Account
  • Account
  • Alertme test
  • Ask Question
  • Connections
  • Cookie-policy
  • Dashboard
  • dashboard
  • DWQA User Profile
  • Edit
  • Edit Company
  • Edit Company
  • edit form 5
  • edit form 8 copy testing page
  • Events
  • Followers
  • Followers
  • Following
  • Following
  • for_companies carousal
  • homepage
  • Investment Opportunities
  • Investment Opportunities test
  • Investment Opportunities with filter
  • judges
  • login
  • Login
  • Logout
  • Logout
  • mailchimp
  • Member Directory
  • Member Directory
  • Mentors Community
  • My Bookmarks
  • my companies
  • My Points
  • My Saved Deals
  • Newsletter
  • Order Received
  • Payment
  • poll test
  • post submitted
  • Privacy Policy
  • profile
  • Questions
  • register
  • Registration
  • Sample Page
  • Sitemap html
  • Sponsorships
  • Submit post
  • Submit your Startup Profile here
  • Subscription
  • team memeber
  • Terms of Use
  • test
  • test
  • testdate
  • Thank You
  • Time Zone Test
  • TIPS X beSUCCESS KOREAN STARTUP SHOWCASE
  • User login
  • wp forms add company
  • you want to logout?

Copyright © 2020 KoreaTechDesk | About Us | Sponsorships| Terms of Use |Privacy Policy |Cookie Policy Contact : press@koreatechdesk.com

No Result
View All Result
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • FinTech
    • Gadgets & Electronics
    • Health & Bio
    • IoT
    • Marketplaces & E-commerce
    • Robotics
    • Transportation & Logistics
    • Investments
    • Ecosystem & Lists
  • Interviews
  • Events
    • ComeUp
    • NextRise
  • Governments
    • KISA
    • KISED
    • KOCCA
    • KOTRA
    • MSS
    • NIPA
    • SBA
  • Programs
    • LAUNCHPAD
    • COMEUP STARS 120
    • K-Startup Grand Challenge
    • TIPS X beSUCCESS Global Project
  • Investment Opportunities
    • Launchpad France Demoday
    • TIPS Global Demoday
    • Launchpad USA Demoday
    • Launchpad Indonesia Demoday
  • Submit an Article
  • Forums
  • register
  • login

Copyright © 2020 KoreaTechDesk | About Us | Sponsorships| Terms of Use |Privacy Policy |Cookie Policy Contact : press@koreatechdesk.com

wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply

Insert/edit link

Enter the destination URL

Or link to existing content

    No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.